{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"101"}],"units":"Participants"}],"description":"Percentage of participants with TEAEs were reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are those events that occurred from first dose date through 30 days after last dose date, or day before subsequent anticancer therapy, whichever occurs first.","groups":[{"description":"Participants received single dose of erdafitinib 10 mg tablet, orally, once daily, starting from Day 1 through Day 7 and from Day 15 through Day 21 and so on, that is 7-day on and off in each subsequent 28-day cycles starting from Cycle 1. Based on serum phosphate (PO4) levels, there was an option to up-titrate erdafitinib dose to 12 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG000","title":"Main Study: Regimen 1: Erdafitinib 10 Milligrams (mg)/ 12 mg"},{"description":"Participants received single dose of erdafitinib 6 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 8 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG001","title":"Main Study: Regimen 2: Erdafitinib 6 mg/ 8 mg"},{"description":"Participants received single dose of erdafitinib 8 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 9 mg, orally, once daily starting from Cycle 1 Day 15 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG002","title":"Main Study: Regimen 3: Erdafitinib 8 mg/ 9 mg"}],"paramType":"NUMBER","populationDescription":"The population included participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From Day 1 up to 6 years 2 months","title":"Main Study: Percentage of Participants With Treatment-emergent Adverse Event (TEAEs)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}